2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide
C22H16F5N5O2 — CID 166931521
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide
2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide (PubChem CID 166931521) has the molecular formula C22H16F5N5O2 and a molecular weight of 477.39 g/mol. Its IUPAC name is 2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide.
Molecular Properties
| Compound Name | 2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide |
|---|---|
| PubChem CID | 166931521 |
| Molecular Formula | C22H16F5N5O2 |
| Molecular Weight | 477.39 g/mol |
| Exact Mass | 477.12 |
| IUPAC Name | 2-fluoro-N-[[2-fluoro-5-(trifluoromethoxy)phenyl]methyl]-3-[2-(methylamino)imidazo[1,2-b]pyridazin-6-yl]benzamide |
| SMILES | CNc1cn2nc(-c3cccc(C(=O)NCc4cc(OC(F)(F)F)ccc4F)c3F)ccc2n1 |
| InChI | InChI=1S/C22H16F5N5O2/c1-28-18-11-32-19(30-18)8-7-17(31-32)14-3-2-4-15(20(14)24)21(33)29-10-12-9-13(5-6-16(12)23)34-22(25,26)27/h2-9,11,28H,10H2,1H3,(H,29,33) |
| InChIKey | ITJUYIAKEYTIMY-UHFFFAOYSA-N |
| XLogP | 4.54 |
| TPSA | 80.55 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 477.39 |
| LogP ≤ 5 | 4.54 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166931521 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.